Picture of Biocept logo

BIOC Biocept Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapValue Trap

Momentum

Relative Strength (%)
1m-12.12%
3m-27.49%
6m-45.45%
1yr-78.34%
Volume Change (%)
10d/3m-20.09%
Price vs... (%)
52w High-82.12%
50d MA-6.03%
200d MA-41.07%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-36.76%
Return on Equity-49.72%
Operating Margin-32.24%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202231st Dec 2023
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2022 / 2023

Blurred out image of Biocept EPS forecast chart

Profile Summary

Biocept, Inc. is a molecular oncology diagnostics company. The Company focuses on developing and commercializing clinical diagnostic laboratory assays designed to identify tumor cells and cell-free tumor deoxyribonucleic acid (DNA) from blood, and cerebrospinal fluid (CSF). Its product is branded and trademarked under the name of CNSide. In addition to CNSide, its current blood-based testing includes its Target Selector technologies, which enables detection of specific gene mutations, such as EGFR, KRAS or BRAF, in cell-free ctDNA from blood samples, as well as specific protein and gene alterations, such as HER2 amplification, in circulating tumor cells (CTCs) isolated from blood. Its multi-modality combination of a cell capture and analysis method used with a cell-free tumor DNA approach provides both high-sensitivity and specificity and is applicable to a range of diagnostic applications in patients with metastatic carcinoma. It provides blood-based liquid biopsy technology.

Directors

Last Annual
December 31st, 2021
Last Interim
September 30th, 2022
Incorporated
June 28th, 2013
Public Since
February 5th, 2014
No. of Shareholders
11
No. of Employees
174
Sector
Healthcare Equipment & Supplies
Industry
Healthcare
Exchange
us flag iconNASDAQ Capital Market
Shares in Issue
17,058,770
Blurred out image of a map
Address
9955 Mesa Rim Road, SAN DIEGO, 92121
Web
https://biocept.com/
Phone
+1 8583208200
Contact
Jody Cain
Auditors
Mayer Hoffman & McCann P.C.

BIOC Share Price Performance

Upcoming Events for BIOC

Q4 2022 Biocept Inc Earnings Release

Q1 2023 Biocept Inc Earnings Release

Similar to BIOC

Picture of Accelerate Diagnostics logo

Accelerate Diagnostics

us flag iconNASDAQ Capital Market

Picture of Adapthealth logo

Adapthealth

us flag iconNASDAQ Capital Market

Picture of Aethlon Medical logo

Aethlon Medical

us flag iconNASDAQ Capital Market

Picture of Agendia NV logo

Agendia NV

us flag iconNASDAQ Capital Market

Picture of Akili logo

Akili

us flag iconNASDAQ Capital Market

FAQ

Or unlock with your email

Or unlock with your email